✦ LIBER ✦

377 A phase 1, dose-escalation, safety, pharmacokinetic and pharmacodynamic study of PF-03732010, an IgG1 monoclonal antibody against P-cadherin (placental), administered to adult patients with advanced solid tumors

✍ Scribed by Y. Bang; R. Cohen; T. Blumenkopf; Y. Zhang; M. Toh; A. Countouriotis; D. Shalinsky; S. Zhang; J. Gallo; J. Desai

Book ID: 119603060
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 48 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)72084-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I Pharmacokinetic and Pharmacodyna

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

✍ Paz-Ares, L. G.; Gomez-Roca, C.; Delord, J.-P.; Cervantes, A.; Markman, B.; Corr 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 192 KB

A phase 1 open-label, sequential dose-es

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

✍ Ghamande, Sharad; Lin, Chia-Chi; Cho, Daniel C.; Shapiro, Geoffrey I.; Kwak, Eun 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 318 KB

A phase I pharmacokinetic (PK) and seria

A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 256 KB